Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas. Show more

Location: 1751 River Run, Fort Worth, TX, 76107, United States | Website: https://actuatetherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

116.9M

52 Wk Range

$5.50 - $11.99

Previous Close

$5.96

Open

$5.88

Volume

247,932

Day Range

$5.60 - $6.75

Enterprise Value

113M

Cash

3.889M

Avg Qtr Burn

-5.303M

Insider Ownership

18.94%

Institutional Own.

53.53%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.